SG10201704616SA - Compositions and methods for modulating cell signaling - Google Patents
Compositions and methods for modulating cell signalingInfo
- Publication number
- SG10201704616SA SG10201704616SA SG10201704616SA SG10201704616SA SG10201704616SA SG 10201704616S A SG10201704616S A SG 10201704616SA SG 10201704616S A SG10201704616S A SG 10201704616SA SG 10201704616S A SG10201704616S A SG 10201704616SA SG 10201704616S A SG10201704616S A SG 10201704616SA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- methods
- cell signaling
- modulating cell
- modulating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261722969P | 2012-11-06 | 2012-11-06 | |
US201261722919P | 2012-11-06 | 2012-11-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201704616SA true SG10201704616SA (en) | 2017-07-28 |
Family
ID=50685303
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201704616SA SG10201704616SA (en) | 2012-11-06 | 2013-11-06 | Compositions and methods for modulating cell signaling |
SG11201503271XA SG11201503271XA (en) | 2012-11-06 | 2013-11-06 | Compositions and methods for modulating cell signaling |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201503271XA SG11201503271XA (en) | 2012-11-06 | 2013-11-06 | Compositions and methods for modulating cell signaling |
Country Status (10)
Country | Link |
---|---|
US (2) | US20150284455A1 (en) |
EP (1) | EP2916867A4 (en) |
JP (3) | JP2016500704A (en) |
AU (3) | AU2013341353B2 (en) |
CA (2) | CA2890733A1 (en) |
IL (1) | IL238488B (en) |
MX (1) | MX2015005675A (en) |
SG (2) | SG10201704616SA (en) |
WO (1) | WO2014074532A2 (en) |
ZA (1) | ZA201502884B (en) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11046784B2 (en) | 2006-03-31 | 2021-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
SI2202245T1 (en) | 2007-09-26 | 2016-10-28 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in cdr |
PL2275443T3 (en) | 2008-04-11 | 2016-05-31 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
MX365235B (en) | 2010-11-30 | 2019-05-28 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly. |
JP6774164B2 (en) | 2012-08-24 | 2020-10-21 | 中外製薬株式会社 | Mouse FcγRII specific Fc antibody |
US10919953B2 (en) | 2012-08-24 | 2021-02-16 | Chugai Seiyaku Kabushiki Kaisha | FcgammaRIIB-specific Fc region variant |
WO2014141064A1 (en) | 2013-03-13 | 2014-09-18 | Novartis Ag | Notch2 binding molecules for treating respiratory diseases |
CN113621057A (en) | 2013-04-02 | 2021-11-09 | 中外制药株式会社 | Fc region variants |
IL301607A (en) | 2013-05-06 | 2023-05-01 | Scholar Rock Inc | Compositions and methods for growth factor modulation |
CN107073090A (en) | 2014-04-30 | 2017-08-18 | 哈佛学院董事会 | With reference to vaccine device and kill cancer cell method |
JP6706617B2 (en) * | 2014-11-06 | 2020-06-10 | スカラー ロック インコーポレイテッドScholar Rock,Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
EP3218005B1 (en) | 2014-11-12 | 2023-01-04 | Seagen Inc. | Glycan-interacting compounds and methods of use |
KR102650420B1 (en) * | 2014-12-19 | 2024-03-21 | 추가이 세이야쿠 가부시키가이샤 | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
WO2016115345A1 (en) | 2015-01-14 | 2016-07-21 | The Brigham And Women's Hospital, | Treatment of cancer with anti-lap monoclonal antibodies |
US9969800B2 (en) | 2015-02-05 | 2018-05-15 | Chugai Seiyaku Kabushiki Kaisha | IL-8 antibodies |
WO2017015622A2 (en) * | 2015-07-22 | 2017-01-26 | Scholar Rock, Inc | Gdf11 binding proteins and uses thereof |
CN113896789A (en) | 2015-09-15 | 2022-01-07 | 供石公司 | Anti-pro/latent myostatin antibodies and uses thereof |
DK3354729T3 (en) * | 2015-09-24 | 2024-04-22 | Daiichi Sankyo Co Ltd | ANTI-GARP ANTI-STOCK |
EP3373969A4 (en) | 2015-11-12 | 2019-08-14 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
US11359009B2 (en) | 2015-12-25 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
SG11201805709RA (en) | 2016-01-08 | 2018-07-30 | Scholar Rock Inc | Anti-pro/latent myostatin antibodies and methods of use thereof |
JP7138864B2 (en) | 2016-02-06 | 2022-09-20 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Recapitulation of the hematopoietic niche to reconstitute immunity |
EA201891909A1 (en) | 2016-03-11 | 2019-02-28 | Сколар Рок, Инк. | TGFβ1-BINDING IMMUNOGLOBULINS AND THEIR APPLICATION |
AU2017240074B2 (en) * | 2016-03-31 | 2020-01-02 | Jiangsu Yahong Meditech Co., Ltd. | Combinational uses of Nitroxoline and its analogues with chemotherapies and immunotherapies in the treatment of cancers |
ES2830440T3 (en) | 2016-06-13 | 2021-06-03 | Scholar Rock Inc | Use of myostatin inhibitors and combination therapies |
CN115404196A (en) | 2016-07-13 | 2022-11-29 | 哈佛学院院长等 | Antigen presenting cell mimetic scaffolds and methods of making and using same |
EP3494991A4 (en) | 2016-08-05 | 2020-07-29 | Chugai Seiyaku Kabushiki Kaisha | Composition for prophylaxis or treatment of il-8 related diseases |
WO2018053234A1 (en) * | 2016-09-15 | 2018-03-22 | Acceleron Pharma, Inc. | Twisted gastrulation polypeptides and uses thereof |
JP7198757B2 (en) | 2017-01-06 | 2023-01-04 | スカラー ロック インコーポレイテッド | Methods for treating metabolic disorders by inhibiting myostatin activation |
US11866506B2 (en) | 2017-04-21 | 2024-01-09 | Mellitus, Llc | Anti-CD59 antibodies |
PL3621694T3 (en) | 2017-05-09 | 2024-02-05 | Scholar Rock, Inc. | Lrrc33 inhibitors and use thereof |
EP3694552A1 (en) | 2017-10-10 | 2020-08-19 | Tilos Therapeutics, Inc. | Anti-lap antibodies and uses thereof |
EP3749365A4 (en) * | 2018-01-29 | 2022-01-12 | Ohio State Innovation Foundation | Peptidyl inhibitors of calcineurin-nfat interaction |
DK3677278T3 (en) | 2018-07-11 | 2022-01-10 | Scholar Rock Inc | ISOFORM SELECTIVE TGFBETA1 INHIBITORS AND USE THEREOF |
EP3863722A2 (en) | 2018-10-10 | 2021-08-18 | Tilos Theapeutics, Inc. | Anti-lap antibody variants and uses thereof |
BR112021015056A2 (en) | 2019-01-30 | 2022-01-11 | Scholar Rock Inc | Specific inhibitors of tgf-beta ltbp complexes and uses thereof |
US20240124889A1 (en) | 2019-05-07 | 2024-04-18 | Voyager Therapeutics, Inc. | Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation |
US20220308072A1 (en) | 2019-08-12 | 2022-09-29 | Voyager Therapeutics, Inc. | High-sensitivity immunoassay for the detection of frataxin in biofluids |
EP4021498A4 (en) | 2019-08-28 | 2024-01-03 | Chugai Seiyaku Kabushiki Kaisha | Cross-species anti-latent tgf-beta 1 antibodies and methods of use |
CN111474336B (en) * | 2020-03-21 | 2023-07-28 | 南昌大学 | Preparation method of nickel ferricyanide nanoparticle luminescent aptamer sensor and method for detecting 8-OhdG based on nickel ferricyanide nanoparticle luminescent aptamer sensor |
WO2022099093A1 (en) * | 2020-11-06 | 2022-05-12 | President And Fellows Of Harvard College | Scaffolds for enhancing neutrophils and uses thereof |
US20220184114A1 (en) | 2020-12-14 | 2022-06-16 | Regeneron Pharmaceuticals, Inc. | Methods Of Treating Metabolic Disorders And Cardiovascular Disease With Inhibin Subunit Beta E (INHBE) Inhibitors |
CN113061575B (en) * | 2021-03-25 | 2023-04-07 | 中国人民解放军陆军军医大学 | Method for separating and purifying inherent lymphoid cells from colon inherent layer of old mouse |
EP4370148A1 (en) | 2021-07-14 | 2024-05-22 | Scholar Rock, Inc. | Ltbp complex-specific inhibitors of tgf beta1 and uses thereof |
CN115286701A (en) * | 2022-03-07 | 2022-11-04 | 江苏靶标生物医药研究所有限公司 | Target for regulating intestinal mucosa homeostasis or inflammatory bowel disease of mammals and application thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5262319A (en) * | 1985-04-19 | 1993-11-16 | Oncogene Science, Inc. | Method for obtaining bone marrow free of tumor cells using transforming growth factor β3 |
JP3452946B2 (en) * | 1992-02-19 | 2003-10-06 | 協和醗酵工業株式会社 | Anti-TGF-β masking protein monoclonal antibody |
WO1994009812A1 (en) * | 1992-10-26 | 1994-05-11 | Kirin Brewery Company, Limited | METHOD FOR PRODUCING LARGE LATENT TRANSFORMING GROWTH FACTOR-β COMPLEXES AND LARGE LATENCY ASSOCIATED PEPTIDE |
WO1995026203A1 (en) * | 1994-03-29 | 1995-10-05 | The Victoria University Of Manchester | Wound healing |
US5616561A (en) * | 1995-03-31 | 1997-04-01 | Regents Of The University Of California | TGF-β antagonists as mitigators of radiation-induced tissue damage |
US6656475B1 (en) * | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
WO2005013915A2 (en) * | 2003-08-08 | 2005-02-17 | The Regents Of The University Of California | Novel indications for transforming growth factor-beta regulators |
JPWO2006106599A1 (en) * | 2005-03-01 | 2008-09-11 | 国立大学法人京都大学 | Medicament for the prevention and / or treatment of diseases caused by abnormal enhancement of extracellular domain shedding |
WO2007050793A2 (en) * | 2005-10-25 | 2007-05-03 | The Johns Hopkins University | Methods and compositions for the treatment of marfan syndrome and associated disorders |
CN102027123B (en) * | 2008-03-14 | 2016-03-16 | 人体酶有限公司 | The restructuring of end user's cell expression system produces reliable human protein |
GB0809592D0 (en) * | 2008-05-27 | 2008-07-02 | Imp Innovations Ltd | Biomaterials |
-
2013
- 2013-11-06 WO PCT/US2013/068613 patent/WO2014074532A2/en active Application Filing
- 2013-11-06 US US14/439,284 patent/US20150284455A1/en not_active Abandoned
- 2013-11-06 SG SG10201704616SA patent/SG10201704616SA/en unknown
- 2013-11-06 JP JP2015540878A patent/JP2016500704A/en active Pending
- 2013-11-06 CA CA2890733A patent/CA2890733A1/en not_active Abandoned
- 2013-11-06 MX MX2015005675A patent/MX2015005675A/en unknown
- 2013-11-06 CA CA3023553A patent/CA3023553A1/en not_active Abandoned
- 2013-11-06 SG SG11201503271XA patent/SG11201503271XA/en unknown
- 2013-11-06 AU AU2013341353A patent/AU2013341353B2/en not_active Ceased
- 2013-11-06 EP EP13853885.5A patent/EP2916867A4/en not_active Withdrawn
-
2015
- 2015-04-28 IL IL238488A patent/IL238488B/en active IP Right Grant
- 2015-04-28 ZA ZA2015/02884A patent/ZA201502884B/en unknown
-
2017
- 2017-04-03 JP JP2017073649A patent/JP2017132796A/en not_active Withdrawn
- 2017-06-06 AU AU2017203805A patent/AU2017203805B2/en not_active Ceased
-
2019
- 2019-06-03 JP JP2019103757A patent/JP2019163317A/en active Pending
- 2019-09-26 US US16/583,799 patent/US20200024339A1/en not_active Abandoned
- 2019-11-14 AU AU2019264599A patent/AU2019264599A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2916867A4 (en) | 2016-10-05 |
IL238488A0 (en) | 2015-06-30 |
ZA201502884B (en) | 2016-01-27 |
JP2016500704A (en) | 2016-01-14 |
MX2015005675A (en) | 2016-02-03 |
CA2890733A1 (en) | 2014-05-15 |
US20150284455A1 (en) | 2015-10-08 |
AU2019264599A1 (en) | 2019-12-05 |
CA3023553A1 (en) | 2014-05-15 |
JP2019163317A (en) | 2019-09-26 |
AU2013341353B2 (en) | 2017-03-16 |
IL238488B (en) | 2020-04-30 |
AU2017203805B2 (en) | 2019-08-15 |
US20200024339A1 (en) | 2020-01-23 |
AU2013341353A1 (en) | 2015-05-28 |
JP2017132796A (en) | 2017-08-03 |
SG11201503271XA (en) | 2015-05-28 |
AU2017203805A1 (en) | 2017-06-22 |
EP2916867A2 (en) | 2015-09-16 |
WO2014074532A3 (en) | 2014-06-26 |
WO2014074532A2 (en) | 2014-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201502884B (en) | Compositions and methods for modulating cell signaling | |
HK1211623A1 (en) | Cell lines | |
HK1212597A1 (en) | Compositions for modulating c9orf72 expression c90rf72 | |
ZA201409229B (en) | Compositions and methods for modulating utrn expression | |
IL237156B (en) | Microcapsule compositions and methods | |
EP2850184A4 (en) | Compositions and methods for modulating gene expression | |
EP2850183A4 (en) | Compositions and methods for modulating gene expression | |
AP2014008100A0 (en) | Compositions and methods for modulating hemoglobingene family expression | |
EP2850189A4 (en) | Compositions and methods for modulating gene expression | |
SG11201408697QA (en) | Methods and compositions for natural killer cells | |
PT2906696T (en) | Methods for modulating c9orf72 expression | |
EP2836212A4 (en) | Novel compositions and methods | |
EP2850182A4 (en) | Compositions and methods for modulating atp2a2 expression | |
ZA201300319B (en) | Compositions and methods for modulating the wnt signaling pathway | |
ZA201408594B (en) | Xylitol-based anti-mucosal compositions and related methods and compositions | |
EP2850187A4 (en) | Compositions and methods for modulating pten expression | |
EP2849800A4 (en) | Compositions and methods for modulating bdnf expression | |
HK1205189A1 (en) | Methods and compositions for modulating factor vii expression vii | |
EP2911230A4 (en) | Cell | |
GB201315350D0 (en) | Methods and compositions | |
GB201315347D0 (en) | Methods and compositions | |
HK1220389A1 (en) | Methods and compositions for modulating regulatory cell function | |
HK1210436A1 (en) | Novel cell compositions and methods | |
EP2827861A4 (en) | Composition and methods for cell modulation |